Use of class I histone deacetylase inhibitor romidepsin in combination regimens

References

• Sajan SA, Hawkins RD. Methods for identifying higher-order chromatin structure. Annu Rev Genomics Hum Genet. 2012;13:59–82.
   PubMed Web of Science ®Google Scholar
• Kouzarides T. Chromatin modifications and their function. Cell. 2007;128:693–705.
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769–784.
   PubMed Web of Science ®Google Scholar
• New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol. 2012;6:637–656.
   PubMed Web of Science ®Google Scholar
• Marsoni S, Damia G, Camboni G. A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics 2008;3:164–171.
   PubMed Web of Science ®Google Scholar
• Lehrmann H, Pritchard LL, Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res. 2002;86:41–65.
   PubMed Web of Science ®Google Scholar
• ISTODAX (romidepsin) [package insert]. Summit, NJ: Celgene Corporation; 2014. [cited 2016 Apr 15]. Available from: http://www.istodax.com/wp-content/uploads/ISTODAX_PackageInsert.pdf.
   Google Scholar
• Zolinza (vorinostat) [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2015. [cited 2016 Apr 15]. Available from: https://www.merck.com/product/usa/pi_circulars/z/zolinza/zolinza_pi.pdf.
   Google Scholar
• Beleodaq (belinostat) [package insert]. Irvine, CA: Spectrum Pharmaceuticals; 2014. [cited 2016 Apr 15]. Available from: http://www.sppirx.com/downloads/140703_final-beleodaq-pi-pt-info.pdf.
   Google Scholar
• Farydak (panobinostat) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2016. [cited 2016 Apr 15]. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/farydak.pdf.
   Google Scholar
• NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphomas V.2.2016. [cited 2016 Apr 15]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
   Google Scholar
• Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood 2011;117:6756–6767.
   PubMed Web of Science ®Google Scholar
• Horwitz SM. Management of peripheral T-cell non-Hodgkin’s lymphoma. Curr Opin Oncol. 2007;19:438–443.
   PubMed Web of Science ®Google Scholar
• Foss FM, Carson KR, Pinter-Brown L, et al. Comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE): first detailed report of primary treatment. Blood. 2012;120:Abstract 1614.
   Web of Science ®Google Scholar
• Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970–1976.
   PubMed Web of Science ®Google Scholar
• Jawed SI, Myskowski PL, Horwitz S, et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and sezary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014;70:205.e1–205.e16.
   Web of Science ®Google Scholar
• Demierre M. Mycosis fungoides and sezary syndrome: the burden of pruritus. Commun Oncol. 2010;7:399–404.
   Google Scholar
• Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sézary syndrome. Blood. 2009;114:4337–4353.
   PubMed Web of Science ®Google Scholar
• Parker SR, Bradley B. Treatment of cutaneous T-cell lymphoma/mycosis fungoides. Dermatol Nurs. 2006;18:566–570, 573–575. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17286158.
   PubMedGoogle Scholar
• Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised international society for cutaneous lymphomas/european organisation for research and treatment of cancer staging proposal. J Clin Oncol. 2010;28:4730–4739.
   PubMed Web of Science ®Google Scholar
• Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002;8:718–728.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood. 2001;98:2865–2868.
   PubMed Web of Science ®Google Scholar
• Marshall JL, Rizvi N, Kauh J, et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol. 2002;2:325–332.
   PubMedGoogle Scholar
• Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27:5410–5417.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117:5827–5834.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631–636.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7:11. Available from: http://jhoonline.biomedcentral.com/articles/10.1186/1756-8722-7-11.
   PubMed Web of Science ®Google Scholar
• Pro B, Horwitz SM, Prince HM, et al. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL). Blood. 2014;124:Abstract 1742.
   Web of Science ®Google Scholar
• Whittaker SJ, Demierre M, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485–4491.
   PubMed Web of Science ®Google Scholar
• Kim YH, Demierre MF, Kim EJ, et al. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. Leuk Lymphoma. 2013;54:284–289.
   PubMed Web of Science ®Google Scholar
• Foss F, Coiffier B, Horwitz S, et al. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomark Res. 2014;2:167771-2-16. eCollection 2014.
   PubMedGoogle Scholar
• Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists. Ann Pharmacother. 2003;37:1276–1286.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006;12:3762–3773.
   PubMed Web of Science ®Google Scholar
• Cabell C, Bates S, Piekarz R, et al. Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin. Blood. 2009;114:Abstract 3709.
   Web of Science ®Google Scholar
• Sager PT, Balser B, Wolfson J, et al. Electrocardiographic effects of class 1 selective histone deacetyalse inhibitor romidepsin. Cancer Med. 2015;4:1178–1185.
   PubMed Web of Science ®Google Scholar
• Folotyn (pralatrexate injection) [package insert]. Westminster, CO: Allos Therapeutics, Inc; 2012. [cited 2016 Apr 15]. Available from: http://www.folotyn.com/downloads/2012_05_folotyn_FPI.pdf.
   Google Scholar
• Jain S, Jirau-Serrano X, Zullo KM, et al. Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma. Clin Cancer Res. 2015;21:2096–2106.
   PubMed Web of Science ®Google Scholar
• Revlimid (lenalidomide) [package insert]. Summit, NJ: Celgene Corporation; 2015. [cited 2016 Apr 15]. Available from: http://www.revlimid.com/wp-content/uploads/full-prescribing-information.pdf.
   Google Scholar
• Witzig TE, Vose JM, Moore TD, et al. Results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin’s lymphoma. Blood. 2007;110:Abstract 2560.
   Google Scholar
• Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27:5404–5409.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:4952–4957.
   PubMed Web of Science ®Google Scholar
• Cosenza M, Civallero M, Fiorcari S, et al. Romidepsin synergizes with lenalidomide in T cell lymphoma cell lines by increasing reactive oxygen species and modulating PI3K/AKT and MAPK/ERK signaling pathways. Blood. 2014;124:Abstract 1778.
   Web of Science ®Google Scholar
• Cosenza M, Civallero M, Fiorcari S, et al. Romidepsin and lenalidomide show a synergistic effect in T-cell lymphoma cell lines. Blood. 213:122:Abstract 5148.
   Google Scholar
• Lunning MA, Ruan J, Nair S, et al. A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relaped/refractory lymphoma and myeloma: phase 1 results. J Clin Oncol. 2014;32:Abstract 8582.
   PubMed Web of Science ®Google Scholar
• Mehta-Shah N, Lunning MA, Ruan J, et al. A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma. Hematol Oncol. 2015;33:Abstract 016.
   Google Scholar
• Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15:1311–1318.
   PubMed Web of Science ®Google Scholar
• Chong EA, Ahmadi T, Aqui NA, et al. Combination of lenalidomide and rituximab overcomes rituximab resistance in patients with indolent B-cell and mantle cell lymphomas. Clin Cancer Res. 2015;21:1835–1842.
   PubMed Web of Science ®Google Scholar
• Shimizu R, Kikuchi J, Wada T, et al. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia. 2010;24:1760–1768.
   PubMed Web of Science ®Google Scholar
• Friedberg J, Mahadevan D, Jung J, et al. Phase 2 trial of alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive B- and T-cell non-Hodgkin lymphoma (NHL). Blood. 2011;118:Abstract 95.
   Web of Science ®Google Scholar
• Barr PM, Li H, Spier CM, et al. U.S. intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881). J Clin Oncol. 2014;5s:Abstract 8523.
   Google Scholar
• Zullo K, Guo Y, Cooke L, et al. The investigational aurora A kinase inhibitor alisertib exhibits broad activity in preclinical models of T-cell lymphoma and is highly synergistic with romidepsin. Blood. 2014;124:Abstract 4493.
   Web of Science ®Google Scholar
• Fanale MA, Hagemeister FB, Fayad L, et al. A phase I trial of alisertib plus romidepsin for relapsed/refractroy aggressive B- and T-cell lymphomas. Blood. 2014;124:Abstract 1744.
   Web of Science ®Google Scholar
• Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21:103–107.
   PubMed Web of Science ®Google Scholar
• Belinsky SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res. 2003;63:7089–7093.
   PubMed Web of Science ®Google Scholar
• Dacogen (decitabine) [package insert]. Dublin, CA: Astex Pharmaceuticals, Inc; 2014. [cited 2016 Apr 15]. Available from: http://otsuka-us.com/products/Documents/DACOGEN.PI.pdf.
   Google Scholar
• Zhu WG, Lakshmanan RR, Beal MD, et al. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2001;61:1327–1333.
   PubMed Web of Science ®Google Scholar
• Klisovic MI, Maghraby EA, Parthun MR, et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia. 2003;17:350–358.
   PubMed Web of Science ®Google Scholar
• Shaker S, Bernstein M, Momparler LF, et al. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk Res. 2003;27:437–444.
   PubMed Web of Science ®Google Scholar
• Kalac M, Scotto L, Marchi E, et al. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood. 2011;118:5506–5516.
   PubMed Web of Science ®Google Scholar
• Marchi E, Zullo KM, Amengual JE, et al. The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma. Br J Haematol. 2015; 171:215–226.
   PubMed Web of Science ®Google Scholar
• Palii SS, Van Emburgh BO, Sankpal UT, et al. DNA methylation inhibitor 5-aza-2′-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol. 2008;28:752–771.
   PubMed Web of Science ®Google Scholar
• Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med. 2001;134:573–586.
   PubMed Web of Science ®Google Scholar
• Lu LJ, Randerath K. Long term instability and molecular mechanism of 5-azacytidine-induced DNA hypomethylation in normal and neoplastic tissues in vivo. Mol Pharmacol. 1984;26:594–603.
   PubMed Web of Science ®Google Scholar
• Dupuis J, Morschhauser F, Ghesquieres H, et al. Combination of romidepsin with cyclosphosphamide, doxorubicin, vinrcristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. Lancet Haematol. 2015;2:e160–e165.
   PubMed Web of Science ®Google Scholar
• Delarue R, Zinzani PL, Hertzberg MS, et al. ROCHOP study: a phase III randomized study of CHOP compared to romidepsin-CHOP in untreated peripheral T-cell lymphoma. J Clin Oncol. 2013;31:Abstract TPS8616.
   Web of Science ®Google Scholar
• Zelenetz AD, Hamlin P, Kewalramani T, et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003;14:i5–i10.
   PubMed Web of Science ®Google Scholar
• Chihara D, Oki Y, Fayad L, et al. Phase I study of romidepsin in combination with ICE (ifosfamide, carboplatin, and etoposide) in patients with relapsed or refractory peripheral T-cell lymphoma. Blood. 2014;124:Abstract 1748.
   Google Scholar
• Velcade (bortezomib) [package insert]. Cambridge, MA: Millennium Pharmaceuticals, Inc; 2015. [cited 2016 Apr 15]. Available from: http://www.velcade.com/files/pdfs/velcade_prescribing_information.pdf.
   Google Scholar
• Khan SB, Maududi T, Barton K, et al. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol. 2004;125:156–161.
   PubMed Web of Science ®Google Scholar
• Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006;108:3441–3449.
   PubMed Web of Science ®Google Scholar
• Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res. 2004;10:3839–3852.
   PubMed Web of Science ®Google Scholar
• Sutheesophon K, Kobayashi Y, Takatoku MA, et al. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of bax, which is enhanced by the proteasome inhibitor bortezomib. Acta Haematol. 2006;115:78–90.
   PubMed Web of Science ®Google Scholar
• Kikuchi J, Wada T, Shimizu R, et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood. 2010;116:406–417.
   PubMed Web of Science ®Google Scholar
• Harrison SJ, Quach H, Link E, et al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood. 2011;118:6274–6283.
   PubMed Web of Science ®Google Scholar
• Liu FT, Agrawal SG, Gribben JG, et al. Bortezomib blocks bax degradation in malignant B cells during treatment with TRAIL. Blood. 2008;111:2797–2805.
   PubMed Web of Science ®Google Scholar
• Faderl S, Rai K, Gribben J, et al. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer. 2006;107:916–924.
   PubMed Web of Science ®Google Scholar
• Liu FT, Agrawal SG, Movasaghi Z, et al. Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood. 2008;112:3835–3846.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Shinn C, Ravi R, et al. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood. 1999;94:1401–1408.
   PubMed Web of Science ®Google Scholar
• Aron JL, Parthun MR, Marcucci G, et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood. 2003;102:652–658.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 2005;105:959–967.
   PubMed Web of Science ®Google Scholar
• Dai Y, Chen S, Kramer LB, et al. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin Cancer Res. 2008;14:549–558.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:4293–4297.
   PubMed Web of Science ®Google Scholar
• Cultrera JL, Rosenberg L, McConkey DJ, et al. The histone deacetylase inhibitor vorinostat induces apoptosis in T-cell lymphoma cell lines and synergizes with bortezomib. Blood. 2008;112:Abstract 1587.
   Web of Science ®Google Scholar
• Holkova B, Kmieciak M, Bose P, et al. Phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma: updated results. Blood. 2014;124:Abstract 3050.
   Web of Science ®Google Scholar
• McBride A, Klaus JO, Stockerl-Goldstein K. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma. Am J Health Syst Pharm. 2015;72:353–360.
   PubMed Web of Science ®Google Scholar
• Akilov OE, Grant C, Frye R, et al. Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions. Br J Dermatol. 2012;167:194–197.
   PubMed Web of Science ®Google Scholar
• Jones SF, Infante JR, Spigel DR, et al. Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors. Cancer Invest. 2012;30:481–486.
   PubMed Web of Science ®Google Scholar
• Gemzar (gemcitabine for injection) [package insert]. Indianapolis, IN: Lilly USA; 2014. [cited 2016 Apr 15]. Available from: http://pi.lilly.com/us/gemzar.pdf.
   Google Scholar
• Sato N, Ohta T, Kitagawa H, et al. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol. 2004;24:679–685.
   PubMed Web of Science ®Google Scholar
• Rajgolikar G, Chan KK, Wang HC. Effects of a novel antitumor depsipeptide, FR901228, on humanbreast cancer cells. Breast Cancer Res Treat. 1998;51:29–38.
   PubMed Web of Science ®Google Scholar
• Hirokawa Y, Arnold M, Nakajima H, et al. Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Cancer Biol Ther. 2005;4:956–960.
   PubMed Web of Science ®Google Scholar
• Vinodhkumar R, Song YS, Ravikumar V, et al. Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549). Chem Biol Interact. 2007;165:220–229.
   PubMed Web of Science ®Google Scholar
• Yu XD, Wang SY, Chen GA, et al. Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells. Cancer J. 2007;13:105–113.
   PubMed Web of Science ®Google Scholar
• Vinodhkumar R, Song YS, Devaki T. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. Biomed Pharmacother. 2008;62:85–93.
   PubMed Web of Science ®Google Scholar
• Khabele D, Son DS, Parl AK, et al. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. Cancer Biol Ther. 2007;6:795–801.
   PubMed Web of Science ®Google Scholar
• Lowell W, Wick MJ, Campos DR, et al. In vivo evaluation of depsipeptide (FK228) alone or in combination with gemcitabine in two human pancreas tumor xenograft models. Proc Amer Assoc Cancer Res. 2006;66:900–901.
   Google Scholar
• Gerber DE, Skelton R, Dong Y, et al. Phase I and pharmacodynamic study of the histone deacetylase (HDAC) inhibitor romidepsin plus erlotinib in previously treated advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;31:Abstract 8088.
   Web of Science ®Google Scholar
• Janne PA, Johnson BE. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res. 2006;12:4416s–4420s.
   PubMed Web of Science ®Google Scholar
• Zhang W, Peyton M, Xie Y, et al. Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines. J Thorac Oncol. 2009;4:161–166.
   PubMed Web of Science ®Google Scholar
• Burgess AJ, Pavey S, Warrener R, et al. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol. 2001;60:828–837.
   PubMed Web of Science ®Google Scholar
• Cartee L, Wang Z, Decker RH, et al. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Res. 2001;61:2583–2591.
   PubMed Web of Science ®Google Scholar
• Schrump DS, Matthews W, Chen GA, et al. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin Cancer Res. 1998;4:2885–2890.
   PubMed Web of Science ®Google Scholar
• Nguyen DM, Schrump WD, Tsai WS, et al. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway. J Thorac Cardiovasc Surg. 2003;125:1132–1142.
   PubMed Web of Science ®Google Scholar
• Abraxane (paclitaxel protein-bound particles for injectable suspension) [package insert]. Summit, NJ: Celgene Corporation; 2015. [cited 2016 Apr 15]. Available from: http://www.abraxane.com/wp-content/uploads/Abraxane_Prescribing_Information.pdf.
   Google Scholar
• Robertson FM, Chu K, Boley KM, et al. The class I HDAC inhibitor romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis. J Exp Ther Oncol. 2013;10:219–233.
   PubMedGoogle Scholar
• Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28:1145–1153.
   PubMed Web of Science ®Google Scholar
• Wilson AJ, Lalani AS, Wass E, et al. Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer. Gynecol Oncol. 2012;127:579–586.
   PubMed Web of Science ®Google Scholar